GeneDx Holdings Corp. (WGS) FY2025 10-K Annual Report
GeneDx Holdings Corp. (WGS) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 23, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
GeneDx Holdings Corp. FY2025 10-K Analysis
Business Overview
- • Core business model: Provider of clinical exome and genome sequencing diagnostics powered by proprietary GeneDx Infinity™ rare disease dataset
- • New emphasis on rapid and ultraRapid genomes, medium/long-read sequencing, and multimodal genomic analysis expansion in 2025
- • Strategic shift: Accelerating industry leadership through integration of AI-powered variant interpretation and launching global market expansion with Fabric Genomics acquisition
- • Quantitative metric: GeneDx Infinity™ dataset grew 30% in 2025, surpassing prior 24 years combined, includes 2.5M tests and 50% non-European genetic diversity
- • Noteworthy fact: Leveraged AI (Multiscore) and cloud-based platforms to improve interpretation speed and scalability while lowering sequencing costs
Management Discussion & Analysis
- • Revenue and profitability details not provided in the excerpt
- • No segment performance data disclosed
- • No cash flow, capital allocation, or dividend information available
- • Forward-looking statements noted, but no specific management guidance or risk details given
Risk Factors
- • Regulatory risk: $42M settlement agreement with third-party payor for alleged overpayments to Legacy Sema4, $2M remaining payments as of Dec 31, 2025
- • Macroeconomic risk: reliance on reimbursement approvals from commercial and Medicaid payors, with 18% average reimbursement rate increase in 2025 impacting revenue
- • Operational risk: dependency on third-party suppliers for diagnostic test components and data storage, affecting cost and service delivery efficiency
- • Competitive risk: integration risk from Fabric Genomics acquisition to expand AI-enabled genome interpretation amid rapid technology evolution and competitors
- • Financial risk: $57.2M non-cancellable operating leases and $29.2M finance leases creating fixed cash obligations impacting liquidity management
GeneDx Holdings Corp. FY2025 Key Financial MetricsXBRL
Revenue
$428M
▲ +40.0% YoY
Net Income
-$21M
▲ +59.8% YoY
Gross Margin
69.7%
▲ +610bp YoY
Operating Margin
-3.1%
▲ +454bp YoY
Net Margin
-4.9%
▲ +1220bp YoY
ROE
-6.8%
▲ +1450bp YoY
Total Assets
$524M
▲ +24.9% YoY
EPS (Diluted)
$-0.73
▲ +62.4% YoY
Operating Cash Flow
$33M
▲ +216.8% YoY
Source: XBRL data from GeneDx Holdings Corp. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on GeneDx Holdings Corp.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.